Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 14, 2026

‘We get the living daylights taxed out of us’: How billionaires like Elon Musk avoid taxes on their massive wealth

View original at finance.yahoo.com
‘We get the living daylights taxed out of us’: How billionaires like Elon Musk avoid taxes on their massive wealth ALLISON ROBBERT / Getty Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • By borrowing against appreciated stock instead of selling, investors avoid realizing capital gains while keeping assets compounding

    80% confidence
  • Tax avoidance is a key skill to building wealth

    80% confidence
  • The optimal wealth strategy is to invest, borrow against assets, die, place assets in a trust, and pass them to heirs

    80% confidence
  • Americans are taxed on what they earn, what they buy, and what they own

    80% confidence
  • Building wealth creates an obligation to pay as little tax as possible, legally, similar to a prisoner of war's obligation to escape

    80% confidence
  • Wealthy investors should use the buy-borrow-die strategy: buy stocks, never sell, borrow against them, then pass to heirs via trust

    80% confidence
  • Americans are overtaxed and much of government spending goes toward things citizens disagree with

    80% confidence
  • Tax avoidance is a key skill to building wealth

    80% confidence
  • Kiyosaki owns hotels and 15,000 rental properties and makes a lot of money while paying no taxes

    80% confidence
  • Americans are over-taxed and government spending does not align with taxpayers' preferences

    80% confidence
  • Real estate investors using debt can legally pay no taxes due to interest deductibility and other benefits

    80% confidence
  • Kiyosaki is carrying $1.2 billion in debt

    80% confidence
  • Americans face multiple layers of taxation on earnings, purchases, and property ownership

    80% confidence
  • Borrowing against appreciated stock rather than selling avoids capital gains tax while allowing continued compounding

    80% confidence
  • Government should be reduced in size so that people can keep more of their money

    80% confidence
  • Those trying to build wealth have an obligation to legally pay as little tax as possible

    80% confidence
  • Government size should be reduced so people can keep more of their hard-earned money

    80% confidence
  • Kiyosaki is carrying $1.2 billion in debt

    80% confidence
  • Real estate investors can legally use debt to pay no taxes, through deductible interest payments that offset cash flow

    80% confidence
  • Kiyosaki owns hotels and 15,000 rental properties, makes a lot of money, and pays no tax

    80% confidence
  • The primary wealth-building tax strategy is to buy stocks, never sell them, and borrow against them to access liquidity

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
‘We get the living daylights taxed out of us’: How billionaires like Elon Musk avoid taxes on their massive wealth — Source | Via News | Finance Via News